Gland Pharma Appoints Xiao Le as Chief Investment Officer for Singapore Subsidiary
Gland Pharma Ltd 路 Change in Management 路 09 Nov 2026, 3:25 pm
Gland Pharma Appoints Xiao Le as Chief Investment Officer for Singapore Subsidiary Gland Pharma Limited has appointed Mr. Xiao Le as Chief Investment Officer of its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective 9th Nov'26. Reporting to the subsidiary's CEO, Mr. Xiao will oversee global investment opportunities and bolster M&A capabilities across the US, China, and Singapore. He brings over 15 years of healthcare investment and asset management experience, having previously held senior M&A and finance roles at WuXi AppTec, MegaRobo Technologies, and Bank of America Merrill Lynch.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
- Unaudited Financial Results for the Quarter and half year ended September 30, 2026 路 06 Nov 2026
